Glucagon receptors and GLP1 receptors are activated by OXM, exhibiting a more dynamic range of effects that are more likely to correspond with changing health gain objectives in the treatment of obesity [88]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.